HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function.

Abstract
Atomoxetine, a selective norepinephrine transporter blocker, could increase blood pressure by elevating norepinephrine concentration in peripheral sympathetic neurons. This effect may be masked in healthy subjects by central sympatholytic mechanisms. To test this hypothesis we studied the pressor effect of 18 mg of atomoxetine (pediatric dose) in 21 patients with damage of the central (10 subjects) and peripheral (11 subjects) autonomic nervous system. Atomoxetine was administered in a randomized, crossover, placebo-controlled fashion, and blood pressure and heart rate were measured at baseline and for 60 minutes after drug intake. Atomoxetine acutely increased seated and standing systolic blood pressure in patients with central autonomic failure by 54+/-26 (mean+/-standard deviation; P=0.004) and 45+/-23 mm Hg (P=0.016), respectively, as compared with placebo. At the end of the observation period the mean seated systolic blood pressure in the atomoxetine group was in the hypertensive range (149+/-26, range 113 to 209 mm Hg). However, in patients with peripheral autonomic failure, atomoxetine did not elicit a pressor response; seated and standing systolic blood pressure increased by 4+/-18 mm Hg (P=0.695) and 0.6+/-8 mm Hg (P=0.546) with atomoxetine as compared with placebo. In conclusion, atomoxetine induces a dramatic increase in blood pressure in patients with central autonomic failure even at very low doses. These findings suggest that a functional central sympatholytic pathway is essential to avoid hypertension in patients treated with this drug. Caution should be exercised when this medication is used in patients with milder form of autonomic impairment.
AuthorsCyndya Shibao, Satish R Raj, Alfredo Gamboa, André Diedrich, Leena Choi, Bonnie K Black, David Robertson, Italo Biaggioni
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 50 Issue 1 Pg. 47-53 (Jul 2007) ISSN: 1524-4563 [Electronic] United States
PMID17515448 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic Uptake Inhibitors
  • Neurotransmitter Agents
  • Norepinephrine Plasma Membrane Transport Proteins
  • Propylamines
  • Atomoxetine Hydrochloride
Topics
  • Adrenergic Uptake Inhibitors (administration & dosage, adverse effects, pharmacology)
  • Aged
  • Atomoxetine Hydrochloride
  • Autonomic Nervous System Diseases (metabolism, physiopathology)
  • Blood Pressure (drug effects)
  • Cardiovascular System (physiopathology)
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Hypertension (blood, chemically induced, physiopathology)
  • Male
  • Middle Aged
  • Neurotransmitter Agents (blood)
  • Norepinephrine Plasma Membrane Transport Proteins (antagonists & inhibitors)
  • Posture
  • Propylamines (administration & dosage, adverse effects, pharmacology)
  • Systole

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: